During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

East Asian countries, notably China and South Korea, showed significant growth in cancer clinical trials, correlating with ...

MUD HCT is associated with better survival outcomes and fewer severe complications compared to haploidentical HCT in acute ...

Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...

Reclassified disease response criteria at 28 days of treatment for acute graft-vs-host disease (GVHD) improved prediction of 6-month nonrelapse mortality (NRM) compared with conventional criteria in ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Chronic graft-vs-host disease (GVHD) is a cause of late morbidity and mortality after allogeneic stem cell transplant. During ...

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine ...

October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine ...